Oppenheimer Survey of Patient Therapy Combinations Show Relypsa (RLYP) Concern Overblown
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Relypsa (RLYP) PT Raised to $75 at Wedbush; Misunderstanding Creating Buying Opportunity
October 22, 2015 11:13 AM EDTWedbush analyst Liana Moussato reiterated an Outperform rating and boosted her price target on Relypsa, Inc. (NASDAQ: RLYP) to $75.00 (from $66.00) after the FDA announced approval of patiromer under the brand name Veltassa for the treatment of hyperkalemia.
"As we expected, the FDA approved the use of Veltassa, dosed orally once a day (QD), for the treatment of hyperkalemia. In our... More
Relypsa (RLYP) Pares Gains on Concerns about Veltassa's Label
October 22, 2015 8:14 AM EDTRelypsa (NASDAQ: RLYP) declined pre-market Thursday, reversing earlier gains following FDA approval of Veltassa. Declines appear related to concerns about the drug's label. Analysts at Morgan Stanley reportedly described the label as "highly restrictive" and said it will probably limit demand.
... MoreOppenheimer Remains Bullish on Relypsa (RLYP) Following FDA's Veltassa Approval
October 22, 2015 6:49 AM EDTOppenheimer reiterated an Outperform rating and $55.00 price target on Relypsa, Inc. (NASDAQ: RLYP) after the FDA approved Veltassa once-daily for the treatment of hyperkalemia. Veltassa is expected to be available in the US by the first week of January 2016.
Analyst Ling Wang commented,... More
UPDATE: Relypsa's (RLYP) Veltassa Approved by FDA
October 21, 2015 5:15 PM EDT(Updated - October 21, 2015 5:15 PM EDT)
Relypsa's (NASDAQ: RLYP) Veltassa approved by FDA.
Below is the release from the FDA:
The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.
Too much potassium in the blood can lead to dangerous, even fatal, changes in heart rhythm, said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDAs Center for Drug... More
